Research Articles

Socioeconomic implications of Buruli ulcer in Ghana: a three-year review

This study examines some of the socioeconomic cost of treating 102 cases of Buruli ulcer between 1994 and 1996 at the St. Martin's Catholic Hospital in Agroyesum in the Amansie West district of the Ashanti region of Ghana. Seventy percent of the cases were children (up to 15 years of age). There was no sex difference in the distribution of cases. Hospitalization was prolonged (average = 186 days in 1994, 103 days in 1995, and 102 days in 1996) with no significant age and sex differences. There were 10 limb amputations, 12 patients were left with contracture deformities, one patient lost sight in one eye, and two died of sepsis and tetanus. The average total treatment cost per patient was $966.85 (62% indirect) in 1994, $706.08 (75% indirect) in 1995, and $658.74 (79% indirect) in 1996. With increasing number of cases, high treatment costs, and serious complications, urgent attention should be given to the disease in terms of control and research efforts aimed at early detection and treatment.

This article has been cited by other articles:

				M. Schunk, W. Thompson, E. Klutse, J. Nitschke, K. Opare-Asamoah, R. Thompson, E. Fleischmann, V. Siegmund, K.-H. Herbinger, O. Adjei, et al. Outcome of Patients with Buruli Ulcer after Surgical Treatment with or without Antimycobacterial Treatment in Ghana Am J Trop Med Hyg, July 1, 2009; 81(1): 75 - 81. [Abstract] [Full Text] [PDF]

				Y. Barogui, R. C. Johnson, T. S. van der Werf, G. Sopoh, A. Dossou, P. U. Dijkstra, and Y. Stienstra Functional Limitations after Surgical or Antibiotic Treatment for Buruli Ulcer in Benin Am J Trop Med Hyg, July 1, 2009; 81(1): 82 - 87. [Abstract] [Full Text] [PDF]

				E. Torrado, S. Adusumilli, A. G. Fraga, P. L. C. Small, A. G. Castro, and J. Pedrosa Mycolactone-Mediated Inhibition of Tumor Necrosis Factor Production by Macrophages Infected with Mycobacterium ulcerans Has Implications for the Control of Infection Infect. Immun., August 1, 2007; 75(8): 3979 - 3988. [Abstract] [Full Text] [PDF]

				D. Diaz, H. Dobeli, D. Yeboah-Manu, E. Mensah-Quainoo, A. Friedlein, N. Soder, S. Rondini, T. Bodmer, and G. Pluschke Use of the Immunodominant 18-Kilodalton Small Heat Shock Protein as a Serological Marker for Exposure to Mycobacterium ulcerans Clin. Vaccine Immunol., December 1, 2006; 13(12): 1314 - 1321. [Abstract] [Full Text] [PDF]

				F. NACKERS, M. DRAMAIX, R. C. JOHNSON, C. ZINSOU, A. ROBERT, E. DE BIURRUN BAKEDANO, J. R. GLYNN, F. PORTAELS, and R. TONGLET BCG VACCINE EFFECTIVENESS AGAINST BURULI ULCER: A CASE-CONTROL STUDY IN BENIN. Am J Trop Med Hyg, October 1, 2006; 75(4): 768 - 774. [Abstract] [Full Text] [PDF]

				A. A. Duker, E. J. M. Carranza, and M. Hale Spatial relationship between arsenic in drinking water and Mycobacterium ulcerans infection in the Amansie West district, Ghana Mineralogical Magazine, October 1, 2005; 69(5): 707 - 717. [Abstract] [Full Text] [PDF]

				S. Etuaful, B. Carbonnelle, J. Grosset, S. Lucas, C. Horsfield, R. Phillips, M. Evans, D. Ofori-Adjei, E. Klustse, J. Owusu-Boateng, et al. Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans Antimicrob. Agents Chemother., August 1, 2005; 49(8): 3182 - 3186. [Abstract] [Full Text] [PDF]

				V. Siegmund, O. Adjei, P. Racz, C. Berberich, E. Klutse, F. van Vloten, T. Kruppa, B. Fleischer, and G. Bretzel Dry-Reagent-Based PCR as a Novel Tool for Laboratory Confirmation of Clinically Diagnosed Mycobacterium ulcerans-Associated Disease in Areas in the Tropics Where M. ulcerans Is Endemic J. Clin. Microbiol., January 1, 2005; 43(1): 271 - 276. [Abstract] [Full Text] [PDF]

				H. AIGA, T. AMANO, S. CAIRNCROSS, J. A. DOMAKO, O.-K. NANAS, and S. COLEMAN ASSESSING WATER-RELATED RISK FACTORS FOR BURULI ULCER: A CASE-CONTROL STUDY IN GHANA Am J Trop Med Hyg, October 1, 2004; 71(4): 387 - 392. [Abstract] [Full Text] [PDF]

				R. Phillips, O. Adjei, S. Lucas, N. Benjamin, and M. Wansbrough-Jones Pilot Randomized Double-Blind Trial of Treatment of Mycobacterium ulcerans Disease (Buruli Ulcer) with Topical Nitrogen Oxides Antimicrob. Agents Chemother., August 1, 2004; 48(8): 2866 - 2870. [Abstract] [Full Text] [PDF]

				R. Phillips, S. Kuijper, N. Benjamin, M. Wansbrough-Jones, M. Wilks, and A. H. J. Kolk In Vitro Killing of Mycobacterium ulcerans by Acidified Nitrite Antimicrob. Agents Chemother., August 1, 2004; 48(8): 3130 - 3132. [Abstract] [Full Text] [PDF]

				D. M. N. Okenu, L. O. Ofielu, K. A. Easley, J. Guarner, E. A. Spotts Whitney, P. L. Raghunathan, Y. Stienstra, K. Asamoa, T. S. van der Werf, W. T. A. van der Graaf, et al. Immunoglobulin M Antibody Responses to Mycobacterium ulcerans Allow Discrimination between Cases of Active Buruli Ulcer Disease and Matched Family Controls in Areas Where the Disease Is Endemic Clin. Vaccine Immunol., March 1, 2004; 11(2): 387 - 391. [Abstract] [Full Text] [PDF]

				Y. STIENSTRA, P. U. DIJKSTRA, A. GUEDENON, R. C. JOHNSON, E. O. AMPADU, T. MENSAH, E. Y. KLUTSE, S. ETUAFUL, S. DEEPAK, W. T. A. VAN DER GRAAF, et al. DEVELOPMENT OF A QUESTIONNAIRE ASSESSING BURULI ULCER-INDUCED FUNCTIONAL LIMITATION Am J Trop Med Hyg, March 1, 2004; 70(3): 318 - 322. [Abstract] [Full Text] [PDF]

				E. Weir Buruli ulcer: the third most common mycobacterial infection Can. Med. Assoc. J., June 1, 2002; 166(13): 1691 - 1691. [Full Text] [PDF]

				R. H. Choplin Invited Commentary RadioGraphics, November 1, 1999; 19(6): 1503 - 1505. [Full Text] [PDF]